ARTICLE | Product Development
Industry leaders applaud CVS zero co-pay diabetes drug access
CVS is answering the call to decrease the cost burden of diabetes medications on patients
January 29, 2020 11:45 PM UTC
Updated on Feb 1, 2020 at 2:10 AM UTC
CVS is answering the call to decrease the cost burden of diabetes medications on patients with a new plan that eliminates co-pays, and industry leaders committed to the social contract are applauding the news as a step in the right direction.
On Wednesday, CVS Health Corp. (NYSE:CVS) announced the new RxZERO plan that allows health plan sponsors and employers to offer all types of diabetes medications at zero out-of-pocket costs to members, without raising sponsor costs or increasing premiums or deductibles...